Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3194-3201

  Pasquini, Marcelo C ^a   Devine, Steven ^b   Mendizabal, Adam ^d   Baden, Lindsey R ^e   Wingard, John R ^f   Lazarus, Hillard M ^c   Appelbaum, Frederick R ^g   Keever Taylor, Carolyn A ^a   Horowitz, Mary M ^a   Carter, Shelly ^d   O'Reilly, Richard J ^h   Soiffer, Robert J ^e  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d EMMES   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f FLORIDA STATE UNIVERSITY   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CD34 SELECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MYCOSIS; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTOZOAL INFECTION; RANDOMIZED CONTROLLED TRIAL; SIBLING; SURVIVAL RATE; T CELL DEPLETION; VIRUS INFECTION; WHOLE BODY RADIATION;

ANTIGENS, CD34; CLINICAL TRIALS AS TOPIC; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; SIBLINGS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84866554399     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7071     Document Type: Article

References (34)

1. Socié G, Schmoor C, Bethge WA, et al: Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117:6375-6382, 2011
2. Wagner JE, Thompson JS, Carter SL, et al: Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): A multi-centre, randomised phase II-III trial. Lancet 366:733-741, 2005 (Pubitemid 41207235)
3. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1991
4. Drobyski WR, Hessner MJ, Klein JP, et al: T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94:434-441, 1999 (Pubitemid 29323857)
5. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al: T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 91:1083-1090, 1998 (Pubitemid 28078314)
6. Schattenberg A, De Witte T, Preijers F, et al: Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 75:1356-1363, 1990 (Pubitemid 20107305)
7. Soiffer RJ, Fairclough D, Robertson M, et al: CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89:3039-3047, 1997 (Pubitemid 27172592)
8. Pasquini MC, Wang Z, Horowitz MM, et al: 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders, in Cecka JM, Terazaki PI (eds): Clinical Transplant 2010. Los Angeles, CA, Terasaki Foundation Laboratory, 2011, pp 87-105
9. Devine SM, Carter S, Soiffer RJ, et al: Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the Blood and Marrow Transplant Clinical Trials Network protocol 0303. Biol Blood Marrow Transplant 17:1343-1351, 2011
10. Keever-Taylor CA, Devine SM, Soiffer RJ, et al: Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant 18:690-697, 2012
11. Weisdorf D, Carter S, Confer D, et al: Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing unanswered questions. Biol Blood Marrow Transplant 13:257-262, 2007
12. Barfield RC, Otto M, Houston J, et al: A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6:1-6, 2004 (Pubitemid 38325113)
13. Bornhauser M, Platzbecker U, Theuser C, et al: CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: High risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 118:1095-1103, 2002 (Pubitemid 35025975)
14. Elmaagacli AH, Peceny R, Steckel N, et al: Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101:446-453, 2003 (Pubitemid 36077562)
15. Handgretinger R, Klingebiel T, Lang P, et al: Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27:777-783, 2001 (Pubitemid 32496409)
16. Aversa F, Terenzi A, Tabilio A, et al: Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23:3447-3454, 2005
17. Wingard JR, Carter SL, Walsh TJ, et al: Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111-5118, 2010
18. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
19. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
22. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
23. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
24. Pasquini M: Current use and outcome of hematopoietic stem cell transplantation: Part I - CIBMTR summary slides, 2005. CIBMTR Newsletter 12:5-8, 2005
25. Couban S, Simpson DR, Barnett MJ, et al: A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525-1531, 2002 (Pubitemid 34925122)
26. Stem Cell Trialists' Collaborative Group: Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23:5074-5087, 2005
27. Anasetti C, Logan BR, Lee SJ, et al: Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. Blood 118:1, 2011 (abstr)
28. Flowers MED, Parker PM, Johnston LJ, et al: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 100:415-419, 2002 (Pubitemid 34761101)
29. Das-Gupta EP, Russell NH, Shaw BE, et al: Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant alemtuzumab. Biol Blood Marrow Transplant 13:724-733, 2007 (Pubitemid 46772876)
30. Marks DI, Bird JM, Vettenranta K, et al: T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 6:646-653, 2000
31. Bacigalupo A, Lamparelli T, Barisione G, et al: Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12:560-565, 2006 (Pubitemid 43956361)
32. Soiffer RJ, LeRademacher J, Ho V, et al: Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117:6963-6970, 2011
33. Mohty M, Bay J-O, Faucher C, et al: Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470-476, 2003 (Pubitemid 36841962)
34. Jakubowski AA, Small TN, Young JW, et al: T cell depleted stem-cell transplantation for adults with hematologic malignancies: Sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 110:4552-4559, 2007 (Pubitemid 351377823)